AUG 5·SEC EDGARLow
Anderson Woodrow D purchased $54K of INDV
Anderson Woodrow D (Chief Accounting Officer) purchased 1,500 shares of Indivior Pharmaceuticals, Inc. (INDV) at $36.28 on 2026-08-05.
StockNASDAQ · US · USDHealthcare · Drug Manufacturers - Specialty & Generic
$INDV
Indivior Pharmaceuticals, Inc.
Price · $INDVvia TradingView
AI sentiment · 7d12 articles
- Bullish
- 7
- Neutral
- 5
- Bearish
- 0
Top stories · $INDVMore →
AUG 5·yahoo.com
Indivior Shares Surge After Strong Quarterly Results and Higher 2026 Outlook
Indivior Pharmaceuticals (NASDAQ:INDV) reported Q2 2026 adjusted EPS of $1.15 vs $0.74 expected, and revenue of $343 million vs $284.9 million expected. SUBLOCADE net revenue rose 21% to $253 million. Indivior raised FY2026 revenue guidance to $1.295B-$1.365B and SUBLOCADE guidance to $1.01B-$1.05B. Shares rose 9.22% premarket.
AUG 4·bioxconomy.com
$1.8bn merger unites Supernus and Indivior
Supernus Pharmaceuticals and Indivior agreed to merge in a deal valued at about $1.8 billion. Indivior shareholders will receive 0.2683 Supernus shares each, a stated ~58% premium. Supernus shareholders will own ~58% and Indivior ~42%. Closing is expected in H2 2026, pending approvals, with ~$125 million annual cost synergies by end-2027.
INDV sentiment & insider activity
Over the past 7 days, alphai's AI scored 12 news stories mentioning INDV (Indivior Pharmaceuticals, Inc.). Coverage has skewed bullish: 7 bullish, 5 neutral, and 0 bearish.
Recent INDV coverage spans mergers & acquisitions, insider activity and earnings.
In the last 30 days, INDV insiders filed 2 SEC Form 4 transactions — 1 purchase ($54K) and 1 sale ($765K). The most active reporter was Anderson Woodrow D, Chief Accounting Officer, with 1 filing. 50% of activity was filed under pre-arranged Rule 10b5-1 plans.
What's driving INDV
This is an insider open-market purchase, which can be read as mild positive sentiment but is not a fundamental catalyst by itself.
Raised 2026 guidance tied to record SUBLOCADE sales and higher patient starts increases confidence in sustained OUD franchise momentum.
The premium and expected close window are central for INDV holders, but regulatory approvals remain the main uncertainty.
Near-term trading likely dominated by merger mechanics and deal overhang, despite an earnings beat and strong Sublocade performance.
INDV faces deal-driven rerating tied to the combined CNS-focused portfolio and synergy realization.
alphai scores every news story that mentions INDV with an AI model for sentiment and relevance, and aggregates insider trades from Indivior Pharmaceuticals, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $INDV
Score
Anderson Woodrow D purchased $54K of INDV
Anderson Woodrow D (Chief Accounting Officer) purchased 1,500 shares of Indivior Pharmaceuticals, Inc. (INDV) at $36.28 on 2026-08-05.
1 min readIndivior Shares Surge After Strong Quarterly Results and Higher 2026 Outlook
Indivior Pharmaceuticals (NASDAQ:INDV) reported Q2 2026 adjusted EPS of $1.15 vs $0.74 expected, and revenue of $343 million vs $284.9 million expected. SUBLOCADE net revenue rose 21% to $253 million. Indivior raised FY2026 revenue guidance to $1.295B-$1.365B and SUBLOCADE guidance to $1.01B-$1.05B. Shares rose 9.22% premarket.
4 min read
$1.8bn merger unites Supernus and Indivior
Supernus Pharmaceuticals and Indivior agreed to merge in a deal valued at about $1.8 billion. Indivior shareholders will receive 0.2683 Supernus shares each, a stated ~58% premium. Supernus shareholders will own ~58% and Indivior ~42%. Closing is expected in H2 2026, pending approvals, with ~$125 million annual cost synergies by end-2027.
3 min readINDV to Merge With Supernus, Beats on Q2 Earnings, Raises '26 Outlook
Indivior (INDV) agreed to a tax-free, all-stock merger with Supernus (SUPN). Indivior shareholders will own about 56.5% and Supernus 43.5%. The combined CNS-focused company is expected to close in Q4 2026 and trade on Nasdaq under SUPN. Pro forma: ~$2.2B revenue, $888M adjusted EBITDA, $125M synergies. Indivior Q2 2026: adj. EPS $1.15, revenue $343M.
7 min readSupernus and Indivior merge to create scaled, CNS-focused entity - Pharmaceutical Technology
Supernus Pharmaceuticals and Indivior are planning an all-stock merger to form a CNS-focused biopharma. The deal is expected to produce pro forma net revenue of $2.2bn and about $125m in annual cost synergies. Supernus brings Qelbree and Gocovri; Indivior brings Sublocade, Suboxone and Opvee. If completed in Q4 2026, the combined firm will trade as SUPN on Nasdaq.
4 min readIndivior and Supernus (SUPN) outline tax-free all-stock CNS merger of equals
Indivior and Supernus outlined a proposed tax-free all-stock “merger of equals” between the two companies. Indivior plans to file an SEC Form S-4 with a joint proxy statement/prospectus, and both firms will submit additional SEC documents. Shareholders will receive the definitive joint proxy statement/prospectus when available.
3 min read
Why Supernus Pharmaceuticals Stock Topped the Market Today
Supernus Pharmaceuticals (SUPN) rose 3% after announcing a definitive, tax-free all-stock merger with Indivior Pharmaceuticals (INDV), expected to close in Q4 and subject to approvals. The combined portfolio would include 11 FDA-approved drugs. Supernus reported Q2 revenue up 32% to just over $219M, but a net loss of over $58M and a miss versus EPS profit estimates.
5 min readIndivior Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc Appoints Jack A. Khattar as Chief Executive Officer of Supernus, Inc
Indivior Pharmaceuticals and Artemis Merger Sub agreed to merge with Supernus Pharmaceuticals, with Supernus as the surviving company and a wholly owned subsidiary of Indivior. After the deal, Indivior will be renamed Supernus. Jack A. Khattar will become CEO and CFO Timothy C. Dec will serve as CFO, effective at closing.
4 min read
Futures Rise As Oil Plunge Helps Yields Ease From Nosebleed Highs; All Eyes On Yentervention
US stock index futures rose in premarket as oil fell and bond yields eased, helped by reports of US-Iran talks. S&P futures were up 0.5% and Nasdaq up 0.4%, with Mag 7 mostly higher. Notable movers included ATKR +27% on Prysmian’s $95/share bid, BMY +5% on AstraZeneca acquisition talks, and SRAD -14% after guidance cut.
7 min read
Supernus, Indivior Merger Creates $2.2 Bln CNS Company; Shares Surge In Pre-market
Supernus Pharmaceuticals (SUPN) agreed to merge with Indivior Pharmaceuticals (INDV) in an all-stock deal. The combined CNS biopharma is expected to have about $2.2B in annual revenue, $125M annual cost synergies, and close in Q4 2026. Each SUPN share gets 1.5401 INDV shares, with a $1B special cash dividend to INDV holders. Pre-market, SUPN and INDV rose.
2 min read